Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Zhifei's TB Vaccine Approved to Begin Phase III Trial

publication date: Jan 11, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Chongqing Zhifei Biological Product Co. has been granted SFDA approval to begin a Phase III trial of an existing product, Mycobacterium Vaccae for Injection (Vaccae), as a vaccine for tuberculosis, a currently unmet need. Vaccae is an immune system modulator that the company currently sells as an adjuvant to treat TB. More details....

Stock Symbol: (SHE: 300122)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors